Montelukast Teva (Montelukast Sodium)

Montelukast, the active ingredient in Montelukast Teva, is a leukotriene receptor antagonist presented as an oral tablet for oral use. It is indicated for maintenance therapy of asthma, relief of allergic rhinitis symptoms, and prevention of exercise‑induced bronchospasm in appropriate patients. GNH USA supplies Montelukast Teva as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide.

Montelukast acts on the leukotriene pathway to control inflammatory airway conditions. - Asthma: provides maintenance therapy that reduces the frequency of bronchospastic episodes. - Allergic rhinitis: alleviates nasal congestion, sneezing and itching caused by allergen exposure. - Exercise‑induced bronchospasm: prevents airway narrowing that can occur during physical activity.

Montelukast is generally well tolerated, but adverse reactions can occur.

Common Side Effects: - Headache: mild to moderate intensity. - Abdominal pain: occasional discomfort. - Cough: transient irritation. - Nausea: occasional upset stomach. - Dizziness: brief episodes. - Fatigue: mild tiredness.

Serious or Rare Side Effects: - Allergic reactions: rash, angioedema or anaphylaxis. - Neuropsychiatric events: mood changes, depression or suicidal thoughts. - Hepatic enzyme elevation: abnormal liver function tests. - Severe skin reactions: Stevens‑Johnson syndrome or toxic epidermal necrolysis. - Blood disorders: eosinophilia or neutropenia.

Before initiating therapy, clinicians should consider several safety aspects. - Liver function assessment: monitor patients with existing hepatic disease. - Psychiatric history review: observe for mood alterations or suicidal ideation. - Renal impairment caution: adjust use in severe renal dysfunction. - Hypersensitivity avoidance: do not prescribe to patients with known allergy to montelukast or excipients. - Store at room temperature: keep in the original packaging, protect from moisture and direct sunlight.

Montelukast may interact with other medicines, requiring attention to the interaction level.

Major Interactions (Avoid): - Strong CYP3A4 inducers (e.g., rifampin): may reduce montelukast exposure. - Phenobarbital: can lower therapeutic levels. - Concomitant leukotriene modifiers (e.g., zafirlukast): increase risk of adverse effects.

Moderate Interactions (Monitor Closely):\n- Antidepressants (SSRIs, SNRIs): may heighten neuropsychiatric risk. - Antihistamines: additive sedation in sensitive individuals. - Warfarin: possible variability in INR, requiring closer monitoring.